Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canopy GrowthCGC -0.23%40 Cash-to-Debt is 1.21 as of Jun. 2026, which is at its 10-year median of 1.21. GuruFocus rates CGC with a GF Score™ of 40/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 985 Drug Manufacturers companies, Canopy Growth ranks better than 54.01% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Canopy Growth's cash to debt ratio for the quarter that ended in Jun. 2026 was 1.21.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Canopy Growthcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Canopy Growth's Cash-to-Debt or its related term are showing as below:
CGC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.27 Med: 1.21 Max: 38.3
Current: 1.21
During the past 13 years, Canopy Growth's highest Cash to Debt Ratio was 38.30. The lowest was 0.27. And the median was 1.21.
CGC's Cash-to-Debt is ranked better than 54.01% of 985
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs CGC: 1.21
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Canopy Growth Cash-to-Debt Related Terms
Canopy Growth Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (CGC) has a Cash-to-Debt of 1.21 as of Jun. 2026. This is near median its historical median of 1.21. Over the past decade, Canopy Growth's Cash-to-Debt has ranged from 0.27 to 38.30. According to the industry distribution chart, Canopy Growth ranks #453 out of 985 companies in the Drug Manufacturers industry, placing it in the top 46%.
Is Canopy Growth's Cash-to-Debt too high?
Canopy Growth's current Cash-to-Debt of 1.21 is near median its 10-year median of 1.21. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 38.30. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Canopy Growth's value of 1.21 is 26% above this industry median. Based on the distribution chart, Canopy Growth ranks #453 out of 985 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Canopy Growth has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #453 out of 985 companies for Cash-to-Debt. This puts Canopy Growth in the upper half of its industry. The industry median Cash-to-Debt is 0.96. Canopy Growth's value of 1.21 is 26% above this benchmark. Historically, Canopy Growth's own Cash-to-Debt has ranged from 0.27 to 38.30 over the past decade. While the company's 10-year median is 1.21 vs. the industry median of 0.96, Canopy Growth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current Cash-to-Debt of 1.21 is 26% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Cash-to-Debt is 1.21, which is near median its own 10-year median of 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (CGC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.93 — trading 38.5% above its estimated fair value. The current Cash-to-Debt is 1.21, which is near median its 10-year median of 1.21 and 26% above the Drug Manufacturers industry median of 0.96. Canopy Growth's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Canopy Growth (CGC), the current Cash-to-Debt is 1.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (CGC) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of $0.93 is trading 38.5% above its estimated GF Value™ of $0.67.
GuruFocus considers Canopy Growth to be Significantly Overvalued.
Key valuation signals for CGC:
Cash-to-Debt: 1.21 (near median its 10-year median of 1.21)
GF Value™: $0.67 vs. price of $0.93 (38.5% above fair value)
Industry Position: 26% above the Drug Manufacturers median (#453 of 985)
No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score
Get the complete analysis for CGC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGC has been successfully added to your 
